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Increasing the efficacy of adoptively transferred, tumor antigen specific T cells is a major goal of immunotherapy. Clearly,
a more thorough understanding of the effector phase of T cell responses, within the tumor site itself, would be beneficial. To
examine this issue, we adoptively transferred tumor antigen-specific effector T cells into tumor-bearing mice, then performed
kinetic evaluations of their phenotype, function, and survival in tumors, draining lymph nodes (dLNs), and spleens during
regression of murine fibrosarcomas. Effector function in tumors was quantitated through the use of a novel intratumoral
cytolytic assay. This approach revealed dynamic changes in the phenotype, cytolytic capacity, and viability of tumor infiltrating
effector T cells during the course of tumor regression. Over a period of days, T cells within tumors rapidly transitioned from
a CD25
hi/CD27
hi to a CD25
low/CD27
low phenotype and displayed an increase in cytolytic capacity, indicative of effector
maturation. Simultaneously, however, the viability of maturing T cells within tumors diminished. In contrast, transferred T cells
trafficking through lymphoid organs were much more static, as they maintained a stable phenotype, robust cytolytic activity,
and high viability. Therefore, there exists a marked phenotypic and functional divergence between tumor-infiltrating effector T
cells and their counterparts in lymphoid organs. Our results indicate that the population of tumor-infiltrating T cells is unique
in experiencing rapid effector maturation post-transfer, and suggest that strategies aimed at prolonging the survival of
CD25
low/CD27
low full effectors, which displayed the highest levels of intratumoral cytolytic activity, should enhance the
efficacy of T cell based tumor immunotherapies.
Citation: Norian LA, Allen PM (2007) Rapid Maturation of Effector T Cells in Tumors, but Not Lymphoid Organs, during Tumor Regression. PLoS
ONE 2(9): e821. doi:10.1371/journal.pone.0000821
INTRODUCTION
The use of T cells as a basis for immunotherapy of tumors is an
area of intense investigation [1,2]. Although much progress has
been made, even the most promising clinical trials contain many
patients who fail to achieve objective responses [3], and the
presence of T cells in the peripheral blood or even the tumor site
itself does not always correlate with tumor regression [4,5]. This
suggests that there is still much to be learned regarding the
biological consequences of T cell entry into tumor microenviron-
ments.
Tumors are known to inhibit T cell function in a variety of ways
[2,6], with many mechanisms active primarily within the confines
of the tumor itself. Although tumors can exert systemic effects as
well, often it is only tumor infiltrating T cells that show functional
defects [7,8,9], due to the unique microenvironments that develop
within solid tumor masses [10,11,12]. Although the issue of T cell
function within tumors has been the focus of intense study [13–
17], the full impact of these environments on CTL function and
fate are not yet known, as it has been difficult to directly examine
T cell cytolytic activity within solid tumors and most studies have
focused on tumor-infiltrating lymphocyte function ex vivo. Even
the use of in vivo cytotoxicity (IVC) assays, [18] which allow the
quantitation of T cell cytolytic activity in spleens and lymph nodes
(LNs) of tumor-bearing mice, [19,20] does not address the impact
of the tumor site itself.
In this study, we examined the intratumoral effector phase of a T
cell-mediated antitumor response. We did this by monitoring
potential kinetic alterations in effector T cell phenotype, function
and fate as adoptively transferred effector T cells differentially
trafficked through solid tumors, draining lymph nodes (dLNs) and
spleens during the course of tumor regression. Our goal was to
better understand how entry into the tumor site affects the
capacity of T cells to bring about tumor rejection, a question that
has been the subject of intense investigation [7–9,13–17]. To
provide new insight into this topic, we examined the cytolytic
activity of transferred CTL in the tumor site, as well as in draining
LNs and spleens. We did this by developing an assay that allowed
quantitation of T cell cytolytic activity within tumors, and
performed this in conjunction with IVC assays to examine kinetic
differences in the functional capacity of tumor-infiltrating T cells
versus their lymphoid organ counterparts.
Along with functional evaluations, we performed phenotypic
assessments of transferred T cells during tumor regression. T cells
are known to progress from naive to effector to memory cells over
the course of weeks to months during an immune response [21],
but heterogeneity exists in each of these categories of cells. For
example, phenotypically distinct memory subpopulations differ in
their ability to contribute to recall responses in vivo [22,23,24].
Effector T cells undergo phenotypic and functional conversions
from early effector to full effector status [25,26], and the ability of
transferred tumor-antigen-specific T cells to bring about tumor
regression was found to be dependent upon effector status at the
time of adoptive transfer, with early effectors being most
efficacious in vivo [26]. In several previous studies, T cell function
was linked to surface expression of markers such as CD27 and
Academic Editor: Derya Unutmaz, New York University School of Medicine,
United States of America
Received July 11, 2007; Accepted August 9, 2007; Published September 5, 2007
Copyright:  2007 Norian, Allen. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: NIH grant P50CA94056 (PMA) Cancer Research Institute Samuel and
Ruth Engelberg Fellowship (LAN)
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: lnorian@wustl.edu
PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e821CD62L, among others [24,26–29]. We therefore examined
whether expression levels of these proteins changed in the days
following adoptive transfer of in vitro activated effector T cells,
and if so, whether such changes were associated with differences in
cytolytic activity.
The results described here further our understanding of effector
T cell competency during an ongoing anti-tumor immune
response. We found that following adoptive transfer, effector T
cells infiltrating the tumor microenvironment experienced rapid
phenotypic and functional alterations consistent with continued
effector maturation in vivo. Within tumors, fully matured
CD25
low/CD27
low effector T cell populations possessed the
highest level of cytolytic activity, but also the greatest incidence
of apoptosis. No evidence for effector maturation was found in
transferred T cell populations that trafficked through peripheral
lymphoid organs. Therefore, the effector status and cytolytic
capacity of tumor antigen specific T cells within tumors is
dynamic, rather than constant, and changes markedly during the
course of T cell mediated tumor regression. Therapies aimed at
prolonging the survival of fully matured effectors should enhance
the efficacy of T cell based immunotherapies. In addition, these
findings illustrate the critical importance of evaluating T cell
function and fate within the tumor site during the development of
immunotherapeutic protocols, as highly divergent patterns of T
cell phenotype, function, and fate were present in the tumor
relative to peripheral lymphoid organs.
RESULTS
DUC18 T cells mediate regression of CMS5 tumors
The major focus of this study was to better understand the
consequences of effector T cell entry into the tumor microenvi-
ronment, with a specific emphasis on how this impacted T cell
maturation and cytolytic activity. To do this, we examined the
phenotype, function and fate of effector T cells that were
mediating tumor rejection. To provide a context for our findings,
we simultaneously examined the same parameters in T cells
trafficking through lymphoid organs of these mice. We used the
CMS5 fibrosarcoma model in conjunction with adoptive transfer
of in vitro activated, tumor antigen-specific DUC18 T cells,
because DUC18 effector T cells are readily able to infiltrate these
tumors, and the ensuing tumor regression is well-characterized
[30–33].
DUC18 T cells are specific for a naturally arising tumor-
associated antigen antigen, denoted tERK for tumor ERK,
presented by H2-K
d on CMS5 cells [34]. As such, CMS5 tumors
act as specific targets for activated DUC18 T cells in vivo [30–33].
Transfer of 30610
6 in vitro activated DUC18 T cells caused the
regression of 100% of transplanted CMS5 tumors that had grown
for 8 days prior to T cell transfer (Figure 1A). The kinetics of
tumor regression were very reproducible, in that tumor areas
continued to increase through day 2 after T cell transfer (Figure 1B)
and only declined thereafter, similar to observations in other
murine tumor models [35,36]. By focusing on these early time
points, in which tumor outgrowth and subsequent regression
occurred, we hoped to better understand not only how effector T
cell function differed within the tumor mass relative to distal
lymphoid organs, but also to identify changes that occurred in
each site as the anti-tumor response progressed.
Phenotypic maturation is unique to tumor
infiltrating effector T cells
We began by evaluating the phenotype of transferred effector T
cells at multiple time points during tumor regression. We wanted
to determine the extent to which tumor-infiltrating T cells
experienced phenotypic alterations, and also whether disparities
existed between these cells and their counterparts in lymphoid
organs. Both tumor draining inguinal LNs (dLNs), as a known site
of tERK antigen presentation in this model [30,31,32], and the
spleen, as an indicator of the systemic response, were examined.
We chose to examine CD25, CD27, and CD62L, as these
proteins are important mediators of T cell function, and because
their expression patterns had previously been shown to fluctuate as
T cell effector maturation occurred [25,26,29]. In T cells, CD25
ligation provides signals required for optimal anti-tumor activity
and CTL persistence in vivo [2], whereas CD27 regulates T cell
survival [37], and CD62L mediates T cell trafficking. We therefore
analyzed expression levels of these same markers on Thy1.1
+
DUC18 T cells at the time of T cell transfer, and through day 6
post-transfer in Thy1.2
+ recipient mice.
In vitro activated DUC18 T cells expressed high levels of both
CD25 and CD27 at the time of transfer (day 0), but expression of
CD62L was variable (Figure 2A). When these cells were left in
culture without further stimulation for up to 6 days, the expression
levels of CD25 decreased, while CD27 and CD62L remained
fairly constant. In contrast, when DUC18 effector T cells were
transferred on day 0 into tumor-bearing mice, substantial changes
in the expression of these markers occurred. By day 2 post-
transfer, a striking phenotypic divergence was apparent between
Figure 1. DUC18 CTL mediate regression of CMS5 tumors. 3610
6
CMS5 tumor cells were injected s.c. and were allowed to grow for
8 days prior to transfer of 30610
6 in vitro activated DUC18 T cells. This
transfer protocol was repeated for all subsequent experiments. A)
Tumor sizes for 6 DUC18 T cell
+ recipient and 4 control mice are shown.
Data are representative of 3 experiments. B) Mean tumor sizes +/2 SEM
for 30 DUC18 T cell
+ recipient mice.
doi:10.1371/journal.pone.0000821.g001
Effector T Cell Maturation
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with regard to their CD25 and CD62L expression profiles
(Figure 2B). In addition, as DUC18 CTL mediated tumor
regression over days 4–6, the phenotype of effectors within tumors
changed dramatically; as expected, CD25 and CD27 expression
were markedly down-regulated while mean CD62L expression
remained low. This phenotype is similar to that of pmel-1 CTL
that have matured to a full effector state after successive rounds of
in vitro stimulation [26]. In contrast, the phenotype of DUC18 T
cells in the dLN and spleen remained relatively constant from days
2–6, characterized by low levels of CD25, high CD27, and high
CD62L. Because the phenotype of DUC18 effector T cells
maintained in vitro was distinct from either tumor-infiltrating or
lymphoid organ DUC18 effector T cells, this suggests that the
observed phenotypic variations in vivo occurred in response to
differential signals received post-transfer, and were not the result of
pre-programmed fate decisions. Therefore, within a discrete
population of adoptively transferred effector T cells, phenotypic
maturation occurred only in effector T cells that had infiltrated the
tumor mass.
Figure 2. Divergent phenotypic profiles of tumor-infiltrating and peripheral lymphoid organ DUC18 CTL. Thy1.1 DUC18 T cells were activated for
four days in vitro and transferred i.v. into Thy1.2 CMS5-tumor bearing mice. A) Prior to transfer, some cells were stained for CD25, CD27 and CD62L.
Remaining cells were left in vitro without further stimulation, and were stained for the same markers on days 2 and 6. Data from one experiment,
representative of three, are shown. B) Following DUC18 T cell transfer, dLNs, spleens, and tumors were harvested from mice and stained on days 2,4,
and 6. All analyses were done by gating on live, Thy1.1
+Vb8.3
+ DUC18 T cells. Shown are mean fluorescence intensity +/2 SEM for combined results
from 3 independent experiments, n=8–10 mice at each time point.
doi:10.1371/journal.pone.0000821.g002
Effector T Cell Maturation
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To further our understanding of how the functional capacity of
tumor-infiltrating effector T cells might vary during the course of
tumor rejection, and how this might deviate from the functional
capacity of effector T cells trafficking through peripheral lymphoid
organs, it was necessary to examine T cell cytolytic activity within
tumors. We accomplished this by developing a modification of the
standard IVC assay that allowed us to quantitate target cell lysis
within tumors.
Effector T cell cytolytic activity has been examined in the
spleens and LNs of mice in several model systems using a standard
IVC assay with high and low concentrations of CFSE
[19,20,38,39]. We performed modified IVC experiments, using
splenocytes pulsed with the cognate DUC18 T cell peptide, tERK,
and labeled with CFSE, or splenocytes pulsed with a control
nERK peptide and labeled with TAMRA prior to i.v. injection
into CMS5 tumor-bearing mice. Specific loss of tERK-pulsed
CFSE
+ targets occurred only in the spleens and dLNs of mice that
received DUC18 T cells (Figure 3A). These data recapitulate
findings from other studies in which potent T cell cytolytic activity
could be detected in spleens and lymph nodes of tumor-bearing
mice [19,20].
Our goal was to evaluate cytolytic activity of DUC18 T cells
within tumors, not just spleens and LNs. Surprisingly, after i.v.
injection, no labeled splenocytes were detected in any tumor
harvested (data not shown). For this reason, and because we
wanted to assess killing of tumor targets rather than peptide-pulsed
surrogates, the protocol was further modified by using fluores-
cently labeled tumor cells as targets, and injecting them directly
into established CMS5 tumors (intratumoral, i.t.).
For intratumoral cytotoxicity (ITC) assays, we made use of the
well-described fibrosarcoma lines CMS5 and Meth A, which are
antigenically distinct, yet demonstrate equivalent growth kinetics
after s.c challenge in the absence of tumor antigen specific T cells,
and so are often used jointly in tumor studies [32,34,40,41]. CFSE
labeled CMS5 cells were used as DUC18 specific targets, and in
vitro comparisons demonstrated that both CFSE labeled and
unlabeled CMS5 cells were killed equivalently by DUC18 effector
T cells (data not shown). TAMRA labeled Meth A DIC cells
served as reference cells, as Meth A cells do not express tERK and
are not recognized by DUC18 T cells [30]. The DIC variant of
Meth A is unable to respond to IFNc [42] and was used to
eliminate any potential loss of the reference population of
fluorescently labeled cells due to bystander killing from IFNc
production directed at CMS5 targets, although parental Meth A
cells were also used with similar results (data not shown).
Importantly, both TAMRA
+ Meth A DIC cells and CFSE
+
CMS5 cells show equivalent viability after being injected i.t. at
a 1:1 ratio into CMS5 tumors in mice that lack DUC18 T cells
(Figure 3B), although due to slight variations in the FL
+ cell ratio
in individual mice (ratios as shown: tumor 1=1.13, tumor
2=1.09, tumor 3=0.74), pooled tumors from multiple mice were
used for subsequent experiments. When this was done, the mean
ratio was calculated to be 1.095 CFSE
+ CMS5 cells to 1.0
TAMRA
+ Meth A DIC (n=13 independent experiments)
(Figure 3C). In addition, although fairly large numbers of FL
+
tumor cells were injected i.t., these cells routinely constituted
a minor fraction of the total cell population present within solid
CMS5 tumors (Figure 3B).
To address the possibility that injecting fluorescently labeled
tumor cells directly into solid tumor masses might alter tumor
growth, we routinely measured tumors at critical times. Analysis of
multiple pooled experiments revealed no statistical differences in
tumor sizes due to the i.t. injection of fluorescently labeled cells, or
in the change of tumor sizes in the 24 hours following i.t. injections
(Figure 3D). Thus, Meth A DIC cells are an appropriate reference
population for use with CMS5 tumor cells, and the i.t. injection of
fluorescently labeled tumor cells does not significantly alter solid
tumor outgrowth during the course of the assay.
DUC18 T cell intratumoral cytolytic activity was first examined
at day 4, during active tumor regression (Figure 1). In mice with no
DUC18 T cells, the ratio of fluorescently labeled CMS5 to Meth A
DIC cells again remained close to 1:1 (Figure 3E). In DUC18 T
cell recipients, the ratio of CMS5: Meth A DIC dropped, reflecting
the specific lysis of CFSE
+ CMS5 cells within tumors (ra-
tio=0.59:1). Because tumors in these mice are regressing, there
is a relative increase in the percentages of fluorescently labeled
cells present, as compared to progressively growing control tumors
(Figure 3E). However, analyses for percent specific killing rely
solely upon the ratio of CMS5 to Meth A DIC, so relative
increases in the percentages of fluorescently labeled cells do not
affect calculations or results. When similar experiments were
performed in which activated DUC18 T cells were transferred into
antigen-negative Meth A tumor-bearing mice, no lysis of labeled,
i.t. injected CMS5 targets was observed (data not shown). This
suggests that when cognate antigen is expressed on only a minority
of tumor cells, insufficient numbers of effector T cells are retained
in tumors to bring about detectable lysis of antigen-positive tumor
targets.
Potent CTL intratumoral cytolytic activity is
preceded by a lag phase
After establishing a method for quantitating T cell cytolytic activity
within tumors, we addressed whether cytolytic activity of tumor-
infiltrating T cells increased concurrently with phenotypic
maturation, and whether the kinetics of killing varied between
CTL within tumors and their counterparts in peripheral lymphoid
organs. For these studies, activated DUC18 T cells were
transferred into CMS5 tumor bearing mice on day 0, and ITC
assays were performed from days 2–6. The mean percentage of
intratumoral killing is shown for each of 17 experiments (circles,
Figure 4A), with overall means indicated by bars. Surprisingly,
DUC18 T cell-mediated lysis of target cells was low at day 2, then
increased at days 4 and 6. Modified IVC assays were performed at
each time point to determine if low levels of cytolytic activity
would also be detected in dLNs and spleens at day 2 or whether
this trend was specific to the tumor site. In contrast to what was
observed within tumors, lysis of targets by DUC18 CTL in both
dLNs and spleens was high at day 2, and remained near the upper
limits of quantitation throughout day 6 (Figure 4A).
Observed lysis of target cells is influenced not only by the
cytolytic activity of effector T cells, but also by the numbers of live
effectors present. Therefore, we tracked Thy1.1 marked DUC18
T cells after transfer into Thy1.2 recipients. The numbers of live
Thy1.1
+ DUC18 T cells within tumors increased dramatically
from day 2 through day 4, but then decreased by day 6 as tumor
sizes diminished (Figure 4B). This pattern varied from that
observed in either dLNs or spleens of tumor-bearing mice
(Figure 4B). Of note, Thy1.1
+ DUC18 T cell numbers were
comparable in tumors and dLNs at day 2, even while the amounts
of target cell lysis observed in the two sites were drastically
different.
To gain a sense of how the cytolytic capacity of tumor-
infiltrating DUC18 CTL populations fluctuated over time, we
calculated normalized killing values by dividing the mean %
specific killing at each time point by the mean number of live
Thy1.1 DUC18 T cells present. Doing so revealed that cytolytic
Effector T Cell Maturation
PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e821Figure 3. T cell cytolytic activity in peripheral lymphoid organs and tumors. DUC18 T cells were transferred as in Figure 1. A) On day 4, 5610
6 each
TAMRA
+ control cells and CFSE
+ targets were injected i.v. Spleens and dLNs were harvested and analyzed on day 5. Percentages of cells within the
indicated gates are shown. Data are representative of 3 experiments. B) CMS5 cells were injected s.c. and allowed to grow for 8 days. At this time,
3610
6 each TAMRA
+ Meth A reference cells and CFSE
+ CMS5 targets were injected i.t. Tumors were harvested and analyzed on day 9; the percentages
of TAMRA
+ and CFSE
+ cells in individual tumors were determined by flow cytometry. C) The mean ratio +/2 SEM of CFSE
+ CMS5 to TAMRA
+ Meth A
cells was calculated using data from 13 individual mice. D) Tumor areas were measured on day 8 after CMS5 challenge. Four days later, fluorescently
labeled tumor cells were injected as in B. Tumor sizes were measured just prior to i.t. injections and again the following day. Data represent the
means +/2 s.d. for 12 tumors from 4 independent experiments. No statistical difference is present in the size of control versus FL+ tumors at day 13
(p=0.11) or in the change in control versus FL+ tumor sizes from day 12 to day 13 (p=0.40). E) DUC18 T cells were transferred into tumor-bearing
mice as in A. On day 4 post-T cell transfer, fluorescently labeled tumor cells were injected as in B. Tumors were harvested and analyzed on day 5.
Percentages of cells within the indicated gates are shown. Data from 1 experiment are shown; representative of 10.
doi:10.1371/journal.pone.0000821.g003
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PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e821Figure 4. An initial lag phase in cytolytic activity precedes robust T cell mediated killing within tumors. A) ITC assays were performed beginning
on days 2, 4, or 6. For tumors, each point represents the mean percent lysis, derived from 2–3 individual mice, for one experiment. Results from 17
experiments are shown, with overall mean values indicated by bars. For dLN and spleen data, each point represents killing from one mouse, with
overall means indicated by bars. B) Thy1.1
+ DUC18 T cells were transferred on day 0, and organs harvested and analyzed on indicated days. Numbers
of live Thy1.1 DUC18 T cells are plotted (for tumors, p values for day 2 versus day 4=.03, for day 2 versus day 6=.05; for dLNs, p=0.03 for day 2
versus day 4, and p=0.04 for day 2 versus day 6). Points represent individual mice (n=13–20) from 3 experiments. C) Normalized killing values were
calculated by dividing the mean % specific killing by the mean number of live DUC18 T cells present in tumors for each time point. D) Activated
DUC18 T cells were transferred into tumor bearing mice on day 0. Organs were harvested on days 2 and 6, and the percentage of cells expressing
IFNc ex vivo was determined by intracellular cytokine staining, after gating on Thy1.1
+ Vb8.3
+ DUC18 T cells. E) Linear regression analyses for %
specific killing in tumors versus % Meth A reference cells present for all individual mice used in ITC assays shown in A. The slopes were not statistically
different from 0; day 2 p=0.83, day 4 p=.90, day 6 p=.16).
doi:10.1371/journal.pone.0000821.g004
Effector T Cell Maturation
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(Figure 4C), reflecting the observations that target cell lysis
remained elevated even while DUC18 T cell numbers were
decreasing. The cytolytic capacity of DUC18 T cells in dLNs and
spleens was not evaluated, because target lysis in dLNs and spleens
consistently neared the upper limits of the assay. Titrations using
lower numbers of DUC18 T cells could not be performed because
these conditions do not bring about tumor regression. Thus, it is
possible that variations in T cell cytolytic capacity also exist in
these sites.
IFNc is often used as an indicator of effector T cell functional
capacity, and it had previously been shown in another tumor
model that while tumor-antigen specific effector T cells traffic
systemically after adoptive transfer, they produced IFNc only
within the tumor site [43]. The data presented in Figure 4A
showed that transferred DUC18 effector T cells in the dLNs and
spleens of tumor-bearing mice were cytolytically active and able to
mediate robust lysis of exogenous, peptide pulsed splenocyte
targets. We therefore wanted to assess the functional status of
effector T cells in these sites, as well as in tumors, in the absence of
exogenous target cells. Intracellular IFNc staining of Thy1.1
+
DUC18 T cells was conducted at days 2 and 6 post-transfer into
CMS5 tumor bearing mice; no exogenous target cells were given
i.t. or i.v. Similar to the previous study [43], tumor-infiltrating
DUC18 CTL, but not those trafficking through dLNs or spleens,
were found to be producing IFNc when examined ex vivo
(Figure 4D). Therefore, although effector T cells in the dLNs and
spleens are capable of lysing tERK
+ target cells in these sites when
such cells are present, in the absence of exogenous targets, these
DUC18 effectors do not produce IFNc locally.
The results presented thus far suggested that intratumoral T cell
cytolytic activity increased during the course of tumor rejection.
However, the ITC assay measures T cell function in a dynamic
environment during tumor rejection, and it was possible that
increased target cell lysis at days 4 and 6 (Figure 4A) was due to
a decreasing number of unlabeled or cold competitor CMS5
tumor cells present within shrinking tumor masses. If this were
true, the size of the tumor, and not the level of T cell cytolytic
activity, would dictate the amount of target cell lysis observed.
When the percentage of Meth A reference cells present (which
would be high in small tumors, and low in larger tumors) was
plotted against the percentage of specific killing detected, no
positive correlation was observed (Figure 4D). Thus, heightened
lysis of tumor cell targets at days 4 and 6 accurately reflects the net
T cell cytolytic activity present, a product of T cell cytolytic
capacity and T cell numbers, and is not spuriously affected by
decreasing tumor sizes. Taken together, these results clearly show
that the kinetics of killing in tumors differ greatly from what is seen
in the periphery; the initial lag in observed killing was present only
in tumor-infiltrating T cells.
Diminished DUC18 T cell survival within tumors
Limited persistence of CTL following adoptive transfer into
tumor-bearing hosts is one factor that contributes to insufficient
anti-tumor immune responses, and previous studies have shown
that tumor-infiltrating lymphocytes are primed to undergo
apoptosis [14]. The phenotypic data presented in Figure 2 showed
that tumor infiltrating T cells progressively lost expression of
CD27 during the course of tumor regression, while CD27
expression on T cells in peripheral lymphoid organs remained
high. Because CD27 is known to regulate T cell survival [37,44],
this suggested that effector T cells within tumors would display
decreased viability. We examined DUC18 T cell viability by two
methods to determine if differences would be apparent in tumor-
infiltrating cells versus their lymphoid compartment counterparts.
First, we compared the percentages of Thy1.1
+ transferred T cells
that were PI
bright in all three sites at days 2–6 after transfer. Not
surprisingly, there was a slight increase in the percentage of PI
bright
DUC18 T cells in tumors from day 2 through day 6, a trend that
was not observed in dLNs and spleens (Figure 5A). A further
examination of T cells at only day 6 was then done with Annexin
V staining to identify apoptotic cells. Again, the highest
percentages of apoptotic DUC18 T cells were found within
tumors (Figure 5B) and a combined analysis of multiple
experiments illustrated that this trend was consistent and
statistically significant (Figure 5C). This finding is in agreement
with previous reports that found fully differentiated effector T cells
had impaired viability [26]. In summary, effector T cells within
tumors are unique in experiencing phenotypic maturation during
tumor regression, and this is associated concurrently with
increased cytolytic capacity, but also decreased survival.
DISCUSSION
This study provides novel insight into the dynamic nature of T cell
effector function in vivo, and illustrates how the effector phase of
a T cell-mediated immune response is affected by local micro-
environments: solid tumor versus dLN versus spleen. We found
marked differences in the phenotype, kinetics of cytolytic activity,
and viability of tumor antigen-specific T cells in tumors versus
their counterparts in peripheral lymphoid organs, illustrating that
continued effector maturation in vivo is unique to tumor-
infiltrating T cells in this model system. Thus, the effector
competency of tumor-infiltrating T cells can change rapidly during
the course of tumor regression. Because the phenotype, function,
and viability of effector T cells trafficking through peripheral
lymphoid organs remained constant during tumor regression,
these cells did not appear to experience in vivo effector
maturation. These findings illustrate how profoundly local
microenvironments affect T cell responses, and illustrate the
importance of studying T cell function within solid tumors, rather
than in peripheral lymphoid organs. Additionally, our findings
suggest that specifically prolonging the survival of differentiated
CD25
low/CD27
low full effectors within tumors should enhance the
efficacy of T cell mediated anti-tumor immunotherapies.
Use of the ITC assay, in conjunction with standard techniques,
yielded a unique kinetic evaluation of T cell effector maturation in
a population of tumor-infiltrating lymphocytes. At the time of
transfer, our DUC18 CTLs possessed a defined cell phenotype
and were CD25
high/CD27
high/CD62L
int-low. At day 2 after
transfer, cells within tumors largely maintained this phenotype,
and possessed a low level of cytolytic activity. Because relatively
few CTL had infiltrated the tumor mass at this point, the observed
lysis of tumor targets was extremely low and correspondingly,
tumor sizes had not yet begun to decline. This finding provides an
explanation for the initial period of continued tumor outgrowth
that follows adoptive transfer of in vitro activated, tumor antigen
specific T cells in this and other murine tumor models [31,32]. It is
possible that in more highly immunosuppressive tumors, this lag
phase might be extended, contributing to the failure of tumor-
antigen specific T cells to control tumor growth. In the CMS5
model at day 4, the phenotype of effectors in tumors had matured,
and although their cytolytic capacity remained low, the number of
antigen-specific T cells had increased 10 fold. Accordingly,
elevated target cell lysis was observed, and tumor regression
ensued. As CTLs in tumors acquired a CD25
low/CD27
low/
CD62L
int-low full effector phenotype by day 6, their cytolytic
capacity increased dramatically. This was reflected in a continued
diminution of tumor sizes, despite the fact that the numbers of
Effector T Cell Maturation
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programs have been described previously, but in these reports,
effector maturation occurred either in response to successive
rounds of in vitro stimulation over a period of weeks, or over
a period of weeks to months in tumor or viral infection models in
vivo [26,29,45]. In contrast, we found that tumor infiltrating
effector T cells in our model underwent a rapid phenotypic and
functional conversion over a period of days, during the course of
primary tumor regression.
Surprisingly, effector maturation did not occur in dLNs, even
though local antigen presentation is sufficient to induce naive
DUC18T cell proliferation in this model [31]. Throughout the
course of tumor regression, the phenotype of DUC18 T cells in
both dLNs and spleens remained CD25
low/CD27
high/CD62L
high,
and the viability of these cells remained high. Furthermore, when
cytolytic activity was examined in dLNs and spleens of tumor-
bearing mice, we observed high levels of target cell lysis even by
day 2 after T cell transfer. This robust killing was present in both
sites through day 6. Therefore, we observed no phenotypic or
functional changes that are associated with effector maturation. It
is possible that use of a lower dose of T cells, at which target cell
lysis was not maximal, would show variations in cytolytic activity
over time in these sites. However, lower T cell doses do not bring
about consistent tumor regression in our model system, a factor
that would confound results and make comparisons inappropriate.
Therefore, we conclude from the IVC experiments only that T
Figure 5. Increased cell death over time in tumor-infiltrating DUC18 CTL. Thy1.1 DUC 18 effector T cells were transferred into tumor-bearing
recipients on day 0. On the indicated days, organs were harvested and stained for Thy1.1/Vb8.3
+ DUC18 T cells. A) The percentage of DUC18 T cells
that were dead was determined by gating on the DUC18 T cell population and analyzing the PI
bright percentage. Data were pooled from 9 mice in 3
independent experiments. B) Organs were harvested on day 6 post-T cell transfer, and samples were stained with Thy1.1, Vb8.3, Annexin V Alexa 488
and 7AAD. Histograms are shown after gating on the DUC18 T cell population, and represent data from a single mouse. C) The percentage of Annexin
V
+ DUC18 T cells is shown, based on the region shown in the histogram in B (p value for % apoptotic DUC18 T cells at day 6 in tumors versus
dLNs=0.0002 and for tumors versus spleens=0.0007). Cumulative data from 3 independent experiments are shown.
doi:10.1371/journal.pone.0000821.g005
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prior to the development of robust cytolytic activity, in contrast to
what occurred with tumor-infiltrating T cells. In support of this
conclusion, experiments in which ITC and IVC assays were
performed simultaneously in tumor-bearing mice showed that
within the same animal, minimal target lysis occurred in tumors at
day 2 post-T cell transfer even while high levels of target lysis were
observed in dLNs and spleens (LAN, unpublished observations).
Our study suggests that there may be site-specific requirements
for effector T cell maturation in order to attain protective immune
responses. Previous work has shown that T cells with a full effector
phenotype display the highest levels of IFNc production and target
lysis in vitro [26], and our tumor-infiltrating full effectors at day 6
possessed the highest cytolytic capacity. We speculate that within
the tumor site, T cells may need to achieve a full effector status
with robust cytolytic potential to overcome local inhibitory
conditions. This opens the possibility that failure to achieve
adequate effector maturation within the tumor microenvironment
could contribute to continued tumor outgrowth in the presence of
tumor antigen-specific T cells. Interestingly, effector T cells at an
earlier maturational stage are able to bring about substantial
cytolysis in the less hostile environments of the dLNs and spleen.
Therefore, even if a linear progression of increasing cytolytic
capacity is present inherently as effector T cells mature from an
early to a full effector status, the effects of local microenvironments
on killing of targets in vivo can not be overlooked.
At this time, many tools are available for studying T cell survival
and trafficking in murine tumor models [46], and much has been
learned about how to enhance anti-tumor responses in cancer
patients as a result. The ITC assay described here provides
a method for examining T cell cytolytic activity within the unique
tumor microenvironment, and its use may shed light on ways to
overcome functional deficiencies in tumor-infiltrating effector T
cells. As performed in this study, the ITC assay uses antigenically
distinct fibrosarcoma cell lines as the reference and target cell
populations. However, many variations could be explored, such as
using a single type of parental versus antigen-transfected cell line;
the critical factor is that a 1:1 ratio of target to reference cells be
maintained intratumorally in the absence of antigen-specific T
cells. In our hands, differentially labeling tumor target populations
with CFSE did not work intratumorally, and neither did using cell
lines that had been stably transfected with the fluorescent protein
dsRed (data not shown). However, increasing the fluorescence
intensity of reference cell population beyond what we were able to
achieve would be beneficial.
Our work here provides the first quantitative evaluation of
intratumoral T cell cytolytic activity. As such, it is a starting point
for this type of research, and important caveats exist that should be
taken into consideration. Foremost is the fact that we used
transplanted fibrosarcomas; the vasculature within these tumors,
and the types of stromal cells present, vary from those found in
other solid tumors, such as carcinomas. Such factors can greatly
influence the ability of T cells to infiltrate tumors and mediate
target killing locally. Additionally, it is possible that the injection of
FL
+ cells directly into tumors could disrupt the local stroma, or
induce a local inflammatory response, altering the access of T cells
to their targets. However, these variables would be equally present
in all tumors harvested for use in the ITC assay, and thus would
not impact conclusions about the kinetics of intratumoral killing,
or, for example, whether a given treatment augmented intratu-
moral T cell cytolytic activity. Finally, because different target cell
types were used for the ITC and IVC assays, it was not possible for
us to directly compare the relative levels of cytolytic activity of
tumor-infiltrating T cells versus their counterparts in peripheral
lymphoid organs. For technical reasons, we were unable to
measure killing of labeled splenocytes within tumors, and were also
unable to measure killing of labeled tumor cells in spleens or LNs
after i.v. injection (data not shown). Therefore, this important issue
could not be addressed using the ITC assay.
Obviously, additional studies using different T cells and tumor
models will be required to test the hypotheses presented here, but
continued examination of effector T cell intratumoral cytolytic
activity should enhance our ability to optimize CTL function
within tumor microenvironments, ultimately leading to more
potent anti-tumor responses in cancer patients.
MATERIALS AND METHODS
Mice
DUC18 TCR transgenic mice [30] are on a BALB/c background
and were bred to Thy1.1 BALB/c mice (provided by Dr. Hyam
Levitsky, Johns Hopkins) to generate Thy1.1
+ DUC18 mice.
BALB/c mice were purchased from the National Cancer Institute.
All animal studies were performed in accordance with institutional
guidelines at the Washington University School of Medicine.
Tumor cells and in vivo challenge
The CMS5 fibrosarcoma cell line, initially derived from a BALB/c
methylcholanthrene-induced fibrosarcoma [47], was cultured as
described [31]. Mice were injected s.c. in the right hind flank with
3610
6 CMS5 cells per mouse in 200 mL of sterile PBS. Tumor
outgrowth studies were conducted as described [31] with ‘‘day 0’’
defined as the time of DUC18 T cell transfer, eight days after
tumor challenge.
DUC18 T cell in vitro activation and adoptive
transfer
Splenocytes from DUC18 mice were stimulated in vitro with one
four-day round of activation [32]. Briefly, 35610
6 bulk spleno-
cytes/ml were cultured with 0.5 mM tERK peptide on day 0, then
were split 1:1 on day 3 and cultured overnight without additional
peptide. Dead cells were removed by Ficoll centrifugation on day
4. Prior to transfer, cells were analyzed by flow cytometry to
determine the percentage of live DUC18 T cells present. For
transfer, 30610
6 live DUC18 T cells were injected i.v. in 200 mL
sterile PBS.
Intratumoral cytotoxicity (ITC) assay
CMS5 tumor cells express the tERK/H-2K
d complex recognized
by the DUC18 TCR, and thus serve as specific targets for DUC18
T cells [30]. Cultured cells were harvested and labeled at 1–5610
7
cells/ml with 5 mM CFSE (Molecular Probes) in HBSS at 37uC
for 5 minutes. Cells were then centrifuged, resuspended in 100%
bovine growth serum (HyClone), and incubated for 5 minutes at
37uC. MethA D IC fibrosarcoma cells (kindly provided by Dr.
Robert Schreiber, Washington University in St. Louis) served as
reference cells; they do not express tERK peptide and are not
recognized by DUC18 T cells [30]. These cells are stable
transfectants lacking the intracellular portion of the IFNcR [42].
Meth A DIC cells were cultured [42], harvested, and labeled with
12 mM TAMRA (Molecular Probes) as outlined above for CFSE.
After counting, CMS5 and Meth A DIC were resuspended at
3610
6 of each cell type/50 ml of sterile PBS and injected i.t. using
a 0.3cc Insulin syringe at 50 ml per mouse.
After 18 hours, tumors were harvested, homogenized, and
collagenase digested [31], then filtered and resuspended in buffer
(PBS with 0.5% BSA, 0.1% NaN3, and 10mM EDTA) for flow
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collected, and tumors from 3 individual mice per treatment group
were pooled for analysis, except where noted. Calculations for %
specific intratumoral cytotoxicity were based on the equation used
to calculate % specific in vivo cytotoxicity [38] such that: %
killing=100-{[(mean ratio of %CMS5 with DUC18 T cells to %
MethA with DUC18 T cells)/(mean ratio of %CMS5 without
DUC18 T cells to % MethA without DUC18 T cells)]6100}.
Spleen and lymph node in vivo cytotoxicity (IVC)
assays
BALB/c splenocytes were either pulsed with 0.5 mM tERK
peptide (DUC18 specific targets) and labeled with 5 mM CFSE as
above, or pulsed with 0.5 mM nERK peptide (a control peptide
derived from native ERK2 not recognized by DUC18 T cells) [30]
and labeled with 12 mM TAMRA as above. Volumes were
adjusted to provide 5610
6 of each live cell type/200 ml sterile
PBS. Suspensions were injected i.v. Approximately 18 hours later,
spleens and tumor draining inguinal lymph nodes were harvested.
Samples were homogenized and prepared for flow cytometric
analysis as described above.
Staining of T cells
Percentages of live Thy1.1
+ DUC 18 T cells were determined by
staining with anti-Thy1.1APC (eBioscience) and propidium iodide;
some samples received anti-Vb8.3 FITC (BD PharMingen), with
anti-CD25 PE (Biolegend), CD27 PE (eBiocience) or CD62L
(Biolegend). Intracellular cytokine staining was performed as
described [48], using anti-Thy1.1 FITC (BD PharMingen) and
anti-IFNc APC (BioLegend). Annexin V Alexa 488 (Molecular
Probes) staining was performed at room temperature in Annexin
binding buffer (0.01M HEPES/NaOH pH 7.4, 0.14M NaCl,
2.5 mM CaCl2) for 15 minutes immediately prior to flow
cytometric analysis, with dead cells being visualized by uptake of
7AAD (7 amino-actinomycin D) (Sigma).
Statistical analyses
Determination of statistical significance was determined through
use of a one or two-tailed Student’s t-Test for independent samples
in Microsoft Excel, or through GraphPad’s Prism software for
linear regression analysis.
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